

Index

Note: Page numbers of article titles are in **boldface** type.

A

Abortion

planned, gestational age at, first-trimester screening effects on, 607–608
spontaneous

in maternal serum abnormalities, 618

in nuchal thickening, 614

Abruption, placental, in thrombophilia, 754

Achondrogenesis, in thickened nuchal translucency, 616

ADAM 12 glycoprotein, for preeclampsia screening, 736

Allele drop-out, in preimplantation genetic testing, 524–525

Alpha-fetoprotein

for Down syndrome screening, 549–552, 566–569, 733

for neural tube defect screening, **721–725**

American College of Medical Genetics, cystic fibrosis screening guidelines of, 536–538

American College of Obstetricians and Gynecologists screening guidelines

cystic fibrosis, 536–538

first-trimester, 605–606

American Society for Reproductive Medicine, preimplantation testing guidelines of, 527

Amniocentesis

cost-effectiveness analysis of, 634

counseling for, 644–645

for cytomegalovirus testing, 715–716

for multiple pregnancies, 646–648

for toxoplasmosis, 711

rate of, first-trimester screening effects on, 606–607

Amnionicity, of twin pregnancies, 574

Analytic framework, in cost-effectiveness analysis, 631–632

Anemia, in parvovirus infections, 713–714

Anencephaly, screening for, 721–725

Aneuploidy. *See also* Down syndrome.

screening for, in multiple pregnancies, 645–646

Angiogenic factors, for preeclampsia screening, 737–738

Anticardiolipin antibodies, 750

Anticoagulants, for thrombophilias, 755–756

Antiphospholipid antibody syndrome, 749–753

Antithrombin deficiency, thrombosis tendency in, 748–749, 754

Aspirin, for thrombophilias, 755

Avidity test

for cytomegalovirus, 715

for toxoplasmosis, 710

B

- Biopsy, for preimplantation genetic testing, 523
- Blastocyst, biopsy of, for preimplantation genetic testing, 523
- Blood-urine-nuchal translucency study, 547
- Body stalk anomaly, in thickened nuchal translucency, 616
- Bowel, echogenic
 - in cystic fibrosis, 539
 - in Down syndrome, 682, 687
- Breast cancer gene, preimplantation testing for, 521

C

- California Genetic Disease Screening Program, 569–570
- Cardiolipin, antibodies to, 750
- Cardiomyopathy, in parvovirus infections, 713
- Cardiovascular system
 - defects of, in thickened nuchal translucency, 614–615, 680
 - ultrasonography of, 579–582
- Carriers, of cystic fibrosis, screening for, 539–540
- Cell adhesion molecules, for preeclampsia screening, 738
- Cerclage, cervical, 701–702
- Cervix
 - cerclage of, 701–702
 - incompetent, 701–703
 - length of, assessment of, 694–698, 701–704
 - trophoblasts from, diagnostic methods using, 656–657
- Chorionic villus sampling
 - counseling for, 644–645
 - for Down syndrome screening, 568
 - for multiple pregnancies, 648–651
 - rate of, first-trimester screening effects on, 606–607
- Chorionicity, of twin pregnancies, 645
- Chromosomal abnormalities, screening for, **545–555**
 - accuracy of, 548–549
 - combined serum and ultrasound for, 549–550
 - current status of, 552–553
 - first- and second-trimester combined, 550–552, 567–570, 596, 671–673
 - in multiple pregnancies, 643–644
 - instant results approach to, **565–571**
 - preimplantation, 521–522
 - serum analytes for, 548–552
 - ultrasound for, 546–550
- Chronicity, of twin pregnancies, 574
- Coagulation disorders, in thrombophilias. *See* Thrombophilias.
- Combination tests, for preeclampsia and intrauterine growth restriction, 739–740
- Combined first- and second-trimester test, for Down syndrome, 550–552, 567–570, 595–596, 671–673
- Combined first-trimester screen, for Down syndrome, 549–550, 567–570, 595–596, 688–690
- Contamination, in preimplantation genetic testing, 524–525

- Contingent screening, for Down syndrome, 551, 567, 597, 638–639, 670, 672–673, 689
- Cordocentesis, for cytomegalovirus testing, 715
- Cost(s), in cost-effectiveness analysis, 632–633
- Cost-benefit analysis, 630, 639
- Cost-effectiveness, of Down syndrome screening, **629–642**
 - economic analysis of, 630–631
 - first-trimester, 635–639
 - methodology for, 631–634, 639–640
- Cost-effectiveness analysis, 630
- Cost-utility analysis, 631
- Counseling
 - for prenatal diagnosis, 644–645
 - genetic. *See* Genetic counseling.
- Cystic fibrosis, **533–543**
 - carriers of, screening for, 539–540
 - ethnic considerations in, 535–538
 - genetics of, 533–534
 - incidence of, 533
 - phenotypic variation in, 534–535
 - preimplantation testing for, 521
 - prenatal diagnosis of, 535–539
 - ultrasound findings with, 539
- Cystic fibrosis transmembrane conductance regulator, 533–538
- Cytomegalovirus infections, 714–716

D

- Dandy-Walker syndrome, in thickened nuchal translucency, 616
- Death, fetal, in thickened nuchal translucency, 614
- Diabetes mellitus, neural tube defect screening results and, 722
- Diaphragmatic hernia, in thickened nuchal translucency, 616
- Digital polymerase chain reaction, 660
- Discounting, in cost-effectiveness analysis, 633
- DNA, free-fetal, diagnostic methods using, 658, 738–739
- Documentation, of multiple pregnancies, 645
- Dominant strategy, in cost-effectiveness analysis, 630
- Doppler evaluation
 - of cardiovascular system, 579–582
 - of placenta, 734
 - of uterine artery, 730–731, 733, 739
- Down syndrome
 - abortion in, first-trimester screening effects on, 607–608
 - screening for
 - clinical implications of, **605–611**
 - cost-effectiveness of, **629–642**
 - evolution of, 678–679
 - first-trimester, **545–555**
 - instant results approach to, **565–571**
 - markers for, 735–736
 - second-trimester, **667–692**

Down syndrome (*continued*)

ultrasonography for. *See* Nuchal translucency; Ultrasonography, for Down syndrome.

Ductus venosus, Doppler evaluation of, 579–580

Dyes, for amniocentesis, in multiple pregnancies, 647

E

Ear length, in Down syndrome, 683–684

Echocardiography, fetal, 614–615

Economic analysis

of first-trimester screening for Down syndrome, 635–638

principles of, 630–631

Education, physician, for first-trimester screening, 605–606

Embryo(s)

biopsy of, for preimplantation genetic testing, 523

excess, ethical problems with, 526

Embryonic mosaicism, preimplantation genetic testing accuracy and, 525

Endothelial cell adhesion molecules, for preeclampsia screening, 738

Endothelial dysfunction, evaluation of, in preeclampsia screening, 737–738

Eng protein, for preeclampsia screening, 737–738

Enzyme-linked immunosorbent assay

for fibronectin, 701

for parvovirus, 712

for toxoplasmosis, 710

Epigenetic methods, for fetal and maternal cell differentiation, 658

“Equal sign,” in nasal bone evaluation, 576–577

Estriol, unconjugated, for Down syndrome screening, 549–552, 566–569, 668–669

Ethics, of preimplantation genetic testing, 525–526

Ethnic considerations, in cystic fibrosis, 535–538

Eugenics, preimplantation genetic testing for, 526

Exponential discounting, in cost-effectiveness analysis, 633

F

Facial cleft, in thickened nuchal translucency, 616

Factor V Leiden, thrombosis tendency in, 748, 751

FASTER trial, for Down syndrome screening, 547–548, 550, 567, 597, 602, 668, 673, 688

Femur, short, in Down syndrome, 681–682, 687

Fetal akinesia deformation sequence, in thickened nuchal translucency, 616

Fetal loss

in amniocentesis, 648

in chorionic villi sampling, 649–650

in maternal serum abnormalities, 618, 620–621

in multiple pregnancies, 648–649

in thrombophilias, 752–753

Fetal Medicine Foundation, first-trimester ultrasound markers standards of, 573–583

Fetus. *See also* Fetal.

cells from, in maternal circulation, diagnostic methods using, 656

parvovirus infections of, 713

trophoblasts from, endocervical, diagnostic methods using, 656–657

ultrasound evaluation of, for cystic fibrosis, 539

- Fibronectin leakage, detection of, 699–704
- Fingers, abnormalities of, in Down syndrome, 683
- First-trimester screening
 - abnormal results of, adverse outcomes after, **613–628**
 - early fetal loss, 618
 - intrauterine growth restriction, 618–619, 622
 - late fetal loss, 618, 620–621
 - preeclampsia, 622
 - preterm birth, 622
 - structural abnormalities, 617
 - thickened nuchal translucency, 613–616
 - clinical implications of, **605–611**
 - biochemistry benefits, 609
 - gestational age at abortion, 607–608
 - invasive prenatal diagnosis rate, 606–607
 - physical education, 605–606
 - ultrasound benefits, 608
 - for chromosomal abnormalities, **545–555, 565–571**
 - for intrauterine growth restriction, **727–746**
 - for preeclampsia, **727–746**
 - genetic counseling for, **557–563**
 - ultrasound markers, **573–592**
 - versus integrated screen, 636–637
- Flt-1 protein, for preeclampsia screening, 737–738
- Fluorescence in situ hybridization, for preimplantation genetic testing, 523–525
- Foot, sandal-gap abnormality of, in Down syndrome, 684
- Fronto-maxillary angle measurement, 577–579

G

- Gender determination
 - noninvasive methods for, 661–662
 - preimplantation, 521
- Genetic counseling, **557–563**
 - first-trimester, **557–563**
 - background of, 557–558
 - challenges to, 559–560
 - focus of, 559
 - objectivity in, 558–559
 - outline for, 560–562
 - for cystic fibrosis carriers, 535–538
- Genetic sonogram, 679–690
- Genetic testing, preimplantation. *See* Preimplantation genetic testing.
- Genomic sequencing, multiple parallel, 660–661
- Genomic testing, preimplantation, 523–524
- Genomics, in preeclampsia, 738–739
- Germline mosaicism, preimplantation genetic testing accuracy and, 525
- Gestational age
 - at abortion, first-trimester screening effects on, 607–608
 - cervical length and fibronectin assessment and, 701–704
 - chromosomal abnormality screen accuracy and, 548–549

Gestational age (*continued*)
 versus Mahalanobis distance, 594
 β_2 -Glycoprotein-1, antibodies to, 750

H

Hand abnormalities, in Down syndrome, 683
 Health care costs, statistics on, 629
 Heart
 defects of, in thickened nuchal translucency, 614–615, 680
 ultrasonography of, 579–582
 Hemostasis disorders, in thrombophilias. *See* Thrombophilias.
 Heparin, for thrombophilias, 755–756
 Hernia, diaphragmatic, in thickened nuchal translucency, 616
 Holoprosencephaly, in thickened nuchal translucency, 616
 Homocysteinemia, thrombosis tendency in, 749, 751–753
 Human chorionic gonadotropin, for Down syndrome screening, 548–552,
 561–562, 566–569, 609, 668–669
 Human leukocyte antigens, preimplantation testing for, 521
 Humerus, short, in Down syndrome, 681–682, 687
 Hydrocele, in maternal serum abnormalities, 622
 Hydrops fetalis, in parvovirus infections, 713–714
 Hypercoagulability, in thrombophilia. *See* Thrombophilias.
 Hyperhomocysteinemia, thrombosis tendency in, 749, 751–753
 Hyperimmune globulin, for cytomegalovirus infections, 716

I

Immunoglobulin(s), measurement of, in toxoplasmosis, 710
 In vitro fertilization
 multiple pregnancies in, 643
 preimplantation genetic testing for, **519–531**
 Increment analysis, in cost-effectiveness analysis, 633
 Independent sequential test, for Down syndrome, 670, 672
 Infections, fetal, in thickened nuchal translucency, 615
 Inhibin A, for Down syndrome screening, 549–552, 566–569, 733
 Insulin resistance, in preeclampsia, 738
 Integrated screen, for Down syndrome, 550–551, 567, 597, 636–638, 670–671, 688–690
 Intrauterine growth restriction, **727–746**
 in maternal serum abnormalities, 618–619, 622
 in thrombophilias, 753–754
 pathophysiology of, 728
 risk factors for, 732–733
 screening for
 clinical factors in, 730
 maternal serum analyses in, 735–740
 placenta perfusion dysfunction–related factors in, 730–731, 733
 placental vascular indices in, 734–735
 PQ ratio in, 733–734
 principles of, 728–730
 Invasive testing, rate of, first-trimester screening effects on, 606–607

J

Jarcho-Levin syndrome, in thickened nuchal translucency, 616

K**Kidney**

- abnormalities of
 - in Down syndrome, 682, 687
 - in maternal serum abnormalities, 622
- polycystic, in thickened nuchal translucency, 616

L

- Likelihood ratios, in screening tests, 729
- Limbs, short, in Down syndrome, 681–682, 687
- Lupus anticoagulant, 750

M

- Mahalanobis distance, for nuchal translucency markers, 594
- Meconium ileus, in cystic fibrosis, 539
- Megacystis, in thickened nuchal translucency, 616
- Mendelian disorders
 - noninvasive testing for, 661
 - preimplantation genetic testing for, 521
- Methylenedihydrofolate reductase defects, thrombosis tendency in, 749, 751–753
- Miscarriage
 - in maternal serum abnormalities, 618
 - in nuchal thickening, 614
- Mitochondrial disorders, preimplantation testing for, 522
- Models, for nuchal translucency measurement, 596–599
- Monte Carlo simulation, 633
- Mosaicism, preimplantation genetic testing accuracy and, 525
- Mucopolysaccharidosis, in thickened nuchal translucency, 616
- Multiple parallel genomic sequencing, 660–661
- Multiple pregnancies, **643–654**
 - anomaly risk in, 643–644
 - counseling on, 644–645
 - documentation of, 645
 - identification of, 645
 - loss rate in, 648–650
 - reduction in, 650–651
 - screening in
 - aneuploidy, 645–646
 - procedures for, 646–651
 - statistics on, 643
 - ultrasound for, 574, 608
- Multiples of the normal median (MoMs)
 - for Down syndrome screening, 547–549
 - for neural tube defect screening, 721–725

N

- Nasal bone evaluation, 576–577, 682–683
- National Human Genome Research Institute, cystic fibrosis screening guidelines of, 536–538
- National Institute of Child Health and Human Development, prenatal diagnosis guidelines of, 634
- National Institutes of Health, cystic fibrosis screening guidelines of, 536–538
- Neural tube defects, screening for, **721–725**
- NIFTY trial, of fetal cells in maternal circulation, 656
- Noninvasive prenatal diagnosis, **655–665**
 - of fetal gender, 661–662
 - of mendelian disorders, 661
 - of Rh disease, 661
 - with digital polymerase chain reaction, 660
 - with endocervical fetal trophoblasts, 656–657
 - with fetal cells in maternal circulation, 656
 - with free-fetal DNA and RNA, 658, 738–739
 - with multiple parallel genomic sequencing, 660–661
 - with RNA–single-nucleotide polymorphism allelic ratios, 659–660
- Nonmendelian disorders, preimplantation genetic testing for, 521
- Noonan syndrome, in thickened nuchal translucency, 616
- Nuchal translucency
 - measurement of, 546–552, 561, 575–576
 - for Down syndrome screening, 668–669, 680–681
 - in instant results approach, **565–571**
 - in multiple pregnancies, 646
 - quality control of, **593–604**
 - errors in, 597–599
 - in multimarker screening, 594–596
 - methods for, 600–602
 - model predictions in, 596–597
 - most discriminatory single marker in, 594
 - results of, 602
 - suboptimal performance of, 599–600
 - thickened, adverse outcomes related to, 614–615

O

- Omphalocele, in thickened nuchal translucency, 616
- Online Mendelian Inheritance in Man, 521
- Oocytes, for in vitro fertilization, 522–523
- OSCAR approach, for Down syndrome screening, 569
- Outcome measure, in cost-effectiveness analysis, 633

P

- PAPP-A protein
 - adverse pregnancy outcomes related to, 617–622
 - for Down syndrome screening, 548–549, 561–562, 595–596, 609, 668–669
- Parvovirus infections, 615, 712–714

- Perspective, in cost-effectiveness analysis, 631
- Physician education, for first-trimester screening, 605–606
- Placenta
 - abruption of, in thrombophilia, 754
 - insufficiency of, in antiphospholipid antibody syndrome, 750
 - pathology of, in preeclampsia, 728
 - three-dimensional imaging of, for preeclampsia, 733
 - vascular indices of, in preeclampsia, 734–735
- Placental growth factor, for preeclampsia screening, 737–738
- Placental protein 13, for preeclampsia screening, 736–737
- Placental specific alleles, RNA from, diagnostic methods using, 659–660
- Plunge technique, for amniocentesis, in multiple pregnancies, 647
- Polar body biopsy, for preimplantation genetic testing, 523
- Policy, for preimplantation genetic testing, 527
- Polygenic disorders, preimplantation testing for, 521
- Polymerase chain reaction
 - digital, 658
 - for preimplantation genetic testing, 523–525
 - for toxoplasmosis, 711
- Polymorphisms, in preeclampsia, 738–739
- PQ ratio, in preeclampsia, 733–734
- Preeclampsia, **727–746**
 - in maternal serum abnormalities, 622
 - in thrombophilias, 753
 - pathophysiology of, 728
 - risk factors for, 732–733
 - screening for
 - clinical factors in, 730
 - maternal serum analyses in, 735–740
 - placenta perfusion dysfunction–related factors in, 730–731, 733
 - placental vascular indices in, 734–735
 - PQ ratio in, 733–734
 - principles of, 728–730
- Preimplantation genetic testing, **519–531**
 - access to, 527
 - adverse outcomes of, 524–525
 - controversies of, 525–527
 - definition of, 520
 - diagnostic accuracy of, 524–525
 - genomic testing in, 523–524
 - history of, 520
 - indications for, 520–522
 - policy on, 527
 - techniques for, 522–523
- Prenatal screening and diagnosis
 - clinical implications of, **605–611**
 - evolution of, 678–679
 - first-trimester
 - adverse outcomes after, **613–628**
 - for chromosomal abnormalities, **545–555, 565–571**
 - for intrauterine growth restriction, **727–746**

Prenatal (*continued*)

- for preeclampsia, **727–746**
 - genetic counseling for, **557–563**
 - ultrasound markers, **573–592**
 - for cystic fibrosis, **533–543**
 - for Down syndrome. *See* Down syndrome.
 - for multiple pregnancies, **643–654**
 - for neural tube defects, **721–725**
 - for preterm labor risks, **693–707**
 - for thrombophilias, **747–760**
 - for toxoplasmosis, 709–712
 - for viral infections, **709–720**
 - noninvasive, **655–665**
 - nuchal translucency measurement in. *See* Nuchal translucency, measurement of.
 - preimplantation, **519–531**
 - second-trimester
 - for intrauterine growth restriction, **727–746**
 - for preeclampsia, **727–746**
 - serum testing, **667–676**
 - ultrasound in, **677–692**
- Preterm labor and birth, **693–707**
- in maternal serum abnormalities, 622
 - prevention of, 701–704
 - risk factors for
 - fibronectin leakage, 699–704
 - list of, 693
 - short cervical length, 694–698, 701–704
 - statistics on, 693
- Probabilities, in cost-effectiveness analysis, 632
- Progesterone, for preterm birth prevention, 702–703
- Protein C deficiency, thrombosis tendency in, 749, 754
- Protein S deficiency, thrombosis tendency in, 749, 754
- Proteomics, in preeclampsia, 738–739
- Prothrombin gene mutation, thrombosis tendency in, 748, 754
- P-selectin, for preeclampsia screening, 738
- Pyelectasis, in Down syndrome, 682, 687
- Pyrimethamine, for toxoplasmosis, 711

Q

- Quad screen, for Down syndrome, 551, 597, 669–671, 689
 - cost-effectiveness of, 634, 636–637
 - in instant results approach, 566–569
 - versus other screens, 595–596
- Quality control, of nuchal translucency measurement, **593–604**
- Quality-adjusted life-years, in cost-utility analysis, 631

R

- Radioimmunoassay, for parvovirus, 712
- Regulation, of preimplantation genetic testing, 527

Research question, in cost-effectiveness analysis, 631

Rh disease, screening for, 661

Risk threshold, in cost-effectiveness analysis, 638–639

RNA

free-fetal, diagnostic methods using, 658

from placental specific alleles, diagnostic methods using, 659–660

S

Sandal-gap abnormality, in Down syndrome, 684

Second-trimester screening

for chromosomal abnormalities, combined with first-trimester screening, 550–552, 567–570, 596, 671–673

for intrauterine growth restriction, **727–746**

for preeclampsia, **727–746**

serum testing for, **667–676**

ultrasound for, **677–692**

Selectins, for preeclampsia screening, 738

Sensitivity analysis, in cost-effectiveness analysis, 633

Sequenom, Inc., technology, 659–660

Sequential screening, for Down syndrome, 551, 567, 597, 636–638, 671–673, 689

Shot-gun sequencing, 660–661

Sludge, cervical, preterm labor risk with, 695

Smith-Lemli-Opitz syndrome, in thickened nuchal translucency, 616

Society for Maternal-Fetal Medicine, on first trimester screening, 607

Spina bifida, screening for, 721–725

Spinal muscular dystrophy, in thickened nuchal translucency, 616

Spiramycin, for toxoplasmosis, 711

Stepwise sequential screening, for Down syndrome, 551, 567, 597, 670, 672

SURPLUS trial, for Down syndrome screening, 550–551

SURUSS trial, for Down syndrome screening, 548, 550, 668

T

Three-dimensional imaging, of placenta, for preeclampsia, 733

Threshold analysis, 633

Thromboembolism, venous, 750–751

Thrombophilias, **747–760**

acquired, 749–750

adverse pregnancy outcomes in, 752–754

definition of, 747

inherited, 748–749

testing for, 754–755

thromboprophylaxis in, 755–756

venous thromboembolism in, 750–751

Time frame, in cost-effectiveness analysis, 631

Toes, sandal-gap abnormality of, in Down syndrome, 684

Toxoplasmosis, 709–712

Transfusions, intrauterine, for anemia in parvovirus infections, 714

Tricuspid valve, Doppler evaluation of, 580–582

Trimethoprim-sulfamethoxazole, for toxoplasmosis, 711

- Triple screen, for Down syndrome, 634, 669–671
- Trisomy 21. *See* Down syndrome.
- Trophoblasts, endocervical, diagnostic methods using, 656–657
- Twin pregnancies
 - anomaly risk in, 643–644
 - chorionicity of, 645
 - counseling on, 644–645
 - loss rate in, 648–650
 - monochorionic, 647–648
 - neural tube defect screening in, 722
 - reduction in, 650–651
 - screening in
 - aneuploidy, 645–646
 - procedures for, 646–651
 - ultrasound for, 574

U

- Ultrasonography. *See also* Doppler evaluation.
 - for cervical length assessment, 696–698
 - for chromosomal abnormalities, 546–550
 - for cystic fibrosis, 539
 - for cytomegalovirus infections, 715–716
 - for Down syndrome, **573–592**, 673. *See also* Nuchal translucency.
 - advantages of, 573–574
 - after positive first-trimester screen, **677–692**
 - benefits of, 608
 - cardiovascular system, 579–582, 680, 682
 - ductus venosus, 579–580
 - ear length, 683–684
 - echogenic bowel, 682, 687
 - femur length, 681–682, 687
 - fronto-maxillary angle, 577–579
 - head and neck, 575–579
 - humerus length, 681–682, 687
 - in multiple gestations, 574
 - kidney anomalies, 682, 687
 - nasal bone, 576–577, 682–683
 - proficiency in, 582
 - protocols for, 582–583
 - soft markers for, 679–685
 - tricuspid valve Doppler evaluation, 580–582
 - for parvovirus infections, 713–714
 - for preeclampsia, 734–735
 - for toxoplasmosis, 711
- Umbilical cord, two-vessel, in Down syndrome, 684
- University of California, San Francisco, instant results screening trimester screening program of, 569
- Uterine artery, Doppler evaluation of, for preeclampsia, 730–731, 733, 739
- Utilities, in cost-effectiveness analysis, 631

V

- Vascular endothelial growth factor, for preeclampsia screening, 737–738
- Vascular indices, placental, in preeclampsia, 734–735
- Velocimetry, uterine artery, for preeclampsia, 730–731, 733, 739
- Venous thromboembolism, 750–751
- Ventricular septal defect, in Down syndrome, 680

W

- Weill-Cornell Medical Center, first-trimester screening program of, 606–607
- Western blot test, for parvovirus, 712

X

- X-linked disorders, preimplantation genetic testing for, 520–521

Z

- Zellweger syndrome, in thickened nuchal translucency, 616